Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Palmitic acid: Practical Protocol and QC Guide
2026-08-17
Palmitic acid (SKU N2456), also known as hexadecanoic acid, provides a characterized saturated long-chain fatty acid for controlled studies of lipid metabolism, protein palmitoylation, metabolic disorder research, and inflammation signaling studies. It is intended for solvent-based preparation rather than direct aqueous dissolution or long-term solution storage, so matched vehicle controls and prompt use are essential.
-
Oxaliplatin Workflows for Resistance Research
2026-08-17
Build more reproducible Oxaliplatin assays by combining controlled DNA-damage exposure, resistance modeling, organoid validation, and mechanism-aware combination testing. This workflow translates evidence on CDK1, PARP1, and olaparib sensitivity into practical choices for cancer chemotherapy research.
-
Cell lysis buffer for WB and IP in CAF Studies
2026-08-16
Cell lysis buffer for WB and IP can support mechanistic studies of cancer-associated fibroblast signaling by combining non-denaturing extraction with protease and phosphatase inhibition. This guide translates the ANGPTL4-IQGAP1 prostate cancer findings into practical decisions for Western blotting, immunoprecipitation, co-IP, and ELISA.
-
Epalrestat and Fructose Metabolism: Assay Strategy
2026-08-15
Epalrestat is an aldose reductase inhibitor that enables researchers to interrogate the upstream polyol pathway, oxidative stress, and endogenous fructose generation. This article translates recent cancer-metabolism findings into a rigorous assay strategy while defining the limits of extrapolating diabetic neuropathy and neuroprotection data to oncology.
-
Rapid Recombinant Annexin V Purification: Study Analysis
2026-08-14
Burger and colleagues developed a short purification workflow for recombinant annexin V that combines mild osmotic shock, reversible calcium-dependent liposome binding, and final ion-exchange chromatography. The approach produced protein sufficiently pure for electrophysiology, crystallography, electron microscopy, and related biophysical studies, illustrating how functional properties can be used as purification handles.
-
Carfilzomib (PR-171): Translational Strategy
2026-08-14
A mechanistic and strategic guide to using Carfilzomib (PR-171) to study proteasome dependence, proteotoxic stress, apoptosis, and combination opportunities in translational cancer research.
-
MK-5108 (VX-689) for Aurora A Research
2026-08-13
MK-5108 (VX-689) combines a subnanomolar Aurora A potency profile with practical workflows for cell-cycle, proliferation, retinoblastoma, and xenograft studies. This guide translates Aurora A biology into assay design, dosing, controls, and troubleshooting decisions for reproducible cancer research.
-
From Biotin Signal to Barrier-Aware Translation
2026-08-13
Streptavidin-Cy3 can serve as more than a fluorescent label: it can become an observability layer for translational workflows that connect molecular identity with localization, transport, and biological response. This article links biotin-based detection strategy with recent biohybrid microrobot research while defining practical validation steps, competitive considerations, and limits to translation.
-
Live-Dead Bacterial Staining Kit for Nanomaterials
2026-08-12
The Live-Dead Bacterial Staining Kit transforms membrane integrity into a mechanistic readout for nanomaterial antibacterial studies. Learn how to interpret NucGreen and EthD-III signals alongside the Fe3O4@ZIF-8 osteomyelitis model without confusing membrane damage with complete loss of bacterial viability.
-
Forskolin in HepaRG Assay Design
2026-08-12
Forskolin is an adenylate cyclase activator that can expose how cAMP signaling interacts with cell state. This guide translates HepaRG differentiation findings into practical decisions for liver, stem-cell, endocrine, and cardiovascular disease research.
-
CTOP for μ-Opioid Receptor Signaling Studies
2026-08-11
CTOP provides a reversible pharmacological way to test whether μ-opioid receptor activation drives signaling, mechanical hypersensitivity, or analgesic tolerance. This workflow connects receptor-level assays with brain-to-spinal circuit experiments while emphasizing controls, local delivery, and practical troubleshooting.
-
Fluorescein TSA Kit: Mechanism and Workflow
2026-08-11
The Fluorescein TSA Fluorescence System Kit uses HRP-mediated tyramide deposition to increase localized fluorescence in fixed-cell and tissue assays. Its fluorescein-labeled tyramide chemistry supports sensitive IHC, ICC, and ISH readouts while preserving a clear distinction between targeted imaging and broad spatial proteomics.
-
SAG and Frataxin-Deficient Astrocyte Neurotoxicity
2026-08-10
Vicente-Acosta and colleagues showed that frataxin depletion drives mitochondrial dysfunction, lipid and autophagy abnormalities, inflammatory astrocyte reactivity, and neuron-toxic secretions. Chronic activation of Smoothened with SAG largely prevented these defects, identifying Hedgehog signaling as a potential regulator of astrocyte-mediated neurodegeneration in Friedreich’s ataxia.
-
SERCA-ER Stress and HSC Mobilization
2026-08-09
Li et al. show that pharmacologic SERCA inhibition with BHQ can enhance hematopoietic stem cell mobilization in mice by linking ER stress to the CaMKII-STAT3-CXCR4 axis. The study provides a mechanistic framework for examining calcium homeostasis disruption as a strategy to improve HSC collection, while leaving dose optimization, safety, and clinical translation unresolved.
-
Stat3 and NF-κB Drive Fyn Neurodegeneration
2026-08-08
A 2024 Disease Models & Mechanisms study uses a neural-specific zebrafish model of constitutively active Fyn to connect kinase signaling with dopaminergic neuron loss and microglial inflammation. Its experiments identify Stat3 as a previously unrecognized Fyn effector and show that Stat3 and NF-κB cooperate in neurodegeneration, providing a mechanistic framework for future pathway-focused studies.